HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar reiterated a Buy rating on TransCode Therapeutics (NASDAQ:RNAZ) and maintained a $3 price target. This reaffirms the firm's positive outlook on the stock.
April 16, 2024 | 2:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TransCode Therapeutics receives a reiterated Buy rating and a $3 price target from HC Wainwright & Co., indicating a strong vote of confidence from the analyst.
The reiteration of a Buy rating and maintenance of a $3 price target by a reputable analyst firm like HC Wainwright & Co. typically signals a positive outlook on the stock, suggesting potential upside. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100